Program Description & Educational Objectives
In this 2-part activity, experts in the treatment of neurodegenerative disorders discuss the latest information pertaining to the management of Alzheimer’s disease and Huntington’s disease. They provide a succinct overview of the pathophysiology and current therapeutic options for these diseases, explore potential cellular targets for the development of novel therapies, and examine recent clinical data pertaining to these therapies.
Upon completion of this activity, participants should be better able to:
- Describe the underlying pathophysiology of Alzheimer’s disease, summarize its current therapeutic options, assess the contribution of altered energy metabolism to the progression of this disorder, and analyze recent clinical trial data related to emerging therapies for this neurodegenerative condition
- Identify the genetic mechanisms responsible for the development of Huntington’s disease, discuss its pathophysiology, describe the clinical symptoms of this disorder, and summarize key data sets pertaining to the established and emerging therapies for this neurodegenerative disorder
Target Audience
This activity has been designed to meet the educational needs of neurologists and other clinicians involved in the management of patients with Alzheimer’s disease and Huntington’s disease.
Requirements for Successful Completion
In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.
Media: Internet
Release and Expiration Dates: February 17, 2010 - February 16, 2011
Time to Complete: 30 minutes
Faculty & Disclosure
Course Director and Interviewee
Rachelle S. Doody, MD, PhD
Professor of Neurology
Effie Marie Cain Chair in Alzheimer's Disease Research
Director, Alzheimer's Disease and Memory Disorders Center
Baylor College of Medicine
Houston, Texas
Rachelle S. Doody, MD, PhD,
has a financial interest/relationship or affiliation in the form of:
Consultant for Allon Therapeutics Inc.; Astellas Pharma US, Inc.; Dainippon Sumitomo Pharma Co., Ltd.; GlaxoSmithKline; Medivation, Inc.; Noven Pharmaceuticals, Inc.; Ocera Therapeutics, Inc.; Otsuka America Pharmaceutical, Inc.; Pfizer Inc; Schering-Plough Corporation; Sonexa Therapeutics, Inc.; Suven Life Sciences Limited; Transition Therapeutics Inc.; and Varinel, Inc.
Grant/Research Support from Elan Pharmaceuticals, Inc.; Janssen, L.P.; Pfizer Inc; and Wyeth Pharmaceuticals Inc.
Advisory Board for Data and Safety Monitoring Board (DSMB) for GlaxoSmithKline; Medivation, Inc.; and Sonexa Therapeutics, Inc.
Interviewee
Ray Dorsey, MD, MBA
Assistant Professor
Department of Neurology
University of Rochester School of Medicine and Dentistry
Rochester, New York
Ray Dorsey, MD, MBA,
has a financial interest/relationship or affiliation in the form of:
Consultant for Lundbeck Research USA, Inc.
Grant/Research Support from Lundbeck Research USA, Inc.; Medivation, Inc.; and Pfizer Inc.
Advisory Board for Lundbeck Research USA, Inc.
Other Financial or Material Support from stock options in Avid Radiopharmaceuticals, Inc.
CME Reviewer
Khurram Bashir, MD, MPH
Associate Professor of Neurology
Department of Neurology
University of Alabama at Birmingham
Birmingham, Alabama
Khurram Bashir, MD, MPH,
currently has no financial interests/relationships or affiliations in relation to this activity.
Content Director
Kirk A. Tacka, PhD
PVI, PeerView Institute for Medical Education, Inc.
Kirk A. Tacka, PhD,
currently has no financial interests/relationships or affiliations in relation to this activity.
Sponsorship, Credit & Support
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Alabama School of Medicine and PVI, PeerView Institute for Medical Education. The University of Alabama School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The University of Alabama School of Medicine designates this educational activity for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
The University of Alabama School of Medicine is an equal opportunity/affirmative action institution.
This activity is supported by an educational grant from 
